October 17, 2019
Shionogi said on October 16 that its anti-flu drug Xofluza (baloxavir marboxil) has been filed in Japan for an additional indication of post-exposure prophylaxis of influenza virus infection. The submission is supported by data from the Japanese PIII BLOCKSTONE study,...read more